Fifth Third Bancorp
VKTX icon

Fifth Third Bancorp’s Viking Therapeutics VKTX Stock Holding History

Fifth Third Bancorp’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257K Buy
6,582
+2,496
+61% +$80.6K ﹤0.01% 2470
2026
Q1 		$133K Buy
4,086
+3,009
+279% +$96.7K ﹤0.01% 2767
2025
Q4 		$37.9K Buy
1,077
+677
+169% +$24K ﹤0.01% 1593
2025
Q3 		$10.5K Buy
400
+200
+100% +$5.97K ﹤0.01% 2129
2025
Q2 		$5.3K Hold
200
– – ﹤0.01% 2181
2025
Q1 		$4.83K Sell
200
-5
-2% -$158 ﹤0.01% 2195
2024
Q4 		$8.25K Hold
205
– – ﹤0.01% 2032
2024
Q3 		$13K Buy
205
+5
+3% +$293 ﹤0.01% 1911
2024
Q2 		$10.6K Buy
+200
New +$13.1K ﹤0.01% 1908
2023
Q3 		– Sell
-200
Closed -$3.24K – 2702
2023
Q2 		$3.24K Buy
+200
New +$4.19K ﹤0.01% 2318
2018
Q3 		– Sell
-5,250
Closed -$50K – 2329
2018
Q2 		$50K Hold
5,250
– – ﹤0.01% 1320
2018
Q1 		$23K Hold
5,250
– – ﹤0.01% 1619
2017
Q4 		$21K Buy
+5,250
New +$15.2K ﹤0.01% 1595

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Fifth Third Bancorp's VKTX Position: Q2 2026 in Review

Fifth Third Bancorp increased its Viking Therapeutics (VKTX) stake by 61% in Q2 2026, buying an estimated $80.6K and bringing the position to 6,582 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #2470.

Fifth Third Bancorp first reported a position in VKTX in Q4 2017 and has held it in 13 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Fifth Third Bancorp held 6,582 shares of Viking Therapeutics worth $257K as of Q2 2026.
  • Fifth Third Bancorp bought 2,496 Viking Therapeutics shares in Q2 2026, an estimated $80.6K.
  • Viking Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #2470 holding.
  • Fifth Third Bancorp first reported a position in Viking Therapeutics in Q4 2017 and has held it in 13 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.